This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eisenberg, R. S. Search for Related Content PubMed PubMed Citation Articles by Eisenberg, R. S. Related Collections Legal/Regulatory Issues Pharmaceuticals Research And Technology

Costs In Context

The Shifting Functional Balance Of Patents And Drug Regulation

Patents are often portrayed as the necessary reward to compensate pharmaceutical firms for the huge costs and risks associated with Food and Drug Administration (FDA)–mandated clinical trials of new drugs. But the relationship between the patent system and other regulation of drugs is more complex than this simple formulation suggests. Drug regulation operates in tandem with patents to make proprietary products profitable, and patents themselves increasingly threaten to limit profitability by diverting profits elsewhere. At the same time, resistance to high drug prices is prompting new state and federal regulatory initiatives that threaten to reduce the value of drug patents. The distinctive intertwining of patents with other regulatory regimes and the shifting role of patents in the biopharmaceutical sector call into question how this singular success story for innovation policy will play out in the future.

                      What's this?

This article has been cited by other articles:

				A. S. Kesselheim, M. A. Fischer, and J. Avorn Extensions Of Intellectual Property Rights And Delayed Adoption Of Generic Drugs: Effects On Medicaid Spending Health Aff., November 1, 2006; 25(6): 1637 - 1647. [Abstract] [Full Text] [PDF]

				R. S. Eisenberg Learning the Value of Drugs -- Is Rofecoxib a Regulatory Success Story? N. Engl. J. Med., March 31, 2005; 352(13): 1285 - 1287. [Full Text] [PDF]

				M. E. Wiktorowicz Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France Journal of Health Politics Policy and Law, August 1, 2003; 28(4): 615 - 658. [Abstract] [PDF]